Press

Vivos Inc. Announces Peer-Reviewed Publication Characterizing PrecisionGel™ Polymer Platform in Elsevier Journal of Drug Delivery Science and Technology

Vivos Inc. Achieves Two Major Operational Milestones: First IsoPet® Shipments from New U.S. Production Facility and Authorization from India’s Nuclear Regulatory Authority for International Manufacturing Center

Human Studies Begin for Hard-to-Treat Cancers. Treatment Invented in Tri-Cities

Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update

Vivos Inc. Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™

Vivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet® Manufacturing

Vivos Inc Summarizes Progress in its Animal Therapy Division

Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics

New Radiation Therapy in New Jersey is Showing Promise in Treating Cancer in Pets

Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025